{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cui Z"],"funding":["National Key Clinical Specialty Discipline Construction Program of China","National Key Research and Development Program of China"],"pagination":["363"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11272681"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["150(7)"],"pubmed_abstract":["<h4>Purpose</h4>IKAROS family zinc finger 3 (IKZF3) is an oncogene involved in different malignancies, particularly in the development and malignant progression of lymphocytes. However, IKZF3 amplification and clinical significance in gastric cancers (GCs) remain unexplored.<h4>Methods</h4>We examined IKZF3 amplification status in 404 GCs with HER2 amplification status using tissue microarray (TMA) and fluorescence in situ hybridization (FISH) assays.<h4>Results</h4>IKZF3 amplification was detected in 6.9% (28/404) of all GC patients, with higher rates in intestinal-type gastric cancer (IGC) (11.22%, 22/196) compared to other types (2.88%, 6/208). HER2 amplification was identified in 16.09% (65/404) of all GC patients, with higher rates in IGC (20.92%, 41/196) compared to other types (11.5"],"journal":["Journal of cancer research and clinical oncology"],"pubmed_title":["IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer."],"pmcid":["PMC11272681"],"funding_grant_id":["YWP2023-001","2021YFF1201001"],"pubmed_authors":["Liang H","Huang J","Huang W","Cui Z","Xu C","Zhang L","Su J","Luan L","Luo R","Yuan W","Hou Y"],"additional_accession":[]},"is_claimable":false,"name":"IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer.","description":"<h4>Purpose</h4>IKAROS family zinc finger 3 (IKZF3) is an oncogene involved in different malignancies, particularly in the development and malignant progression of lymphocytes. However, IKZF3 amplification and clinical significance in gastric cancers (GCs) remain unexplored.<h4>Methods</h4>We examined IKZF3 amplification status in 404 GCs with HER2 amplification status using tissue microarray (TMA) and fluorescence in situ hybridization (FISH) assays.<h4>Results</h4>IKZF3 amplification was detected in 6.9% (28/404) of all GC patients, with higher rates in intestinal-type gastric cancer (IGC) (11.22%, 22/196) compared to other types (2.88%, 6/208). HER2 amplification was identified in 16.09% (65/404) of all GC patients, with higher rates in IGC (20.92%, 41/196) compared to other types (11.5","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-03-31T11:02:03.999Z","creation":"2025-04-06T19:29:11.694Z"},"accession":"S-EPMC11272681","cross_references":{"pubmed":["39052108"],"doi":["10.1007/s00432-024-05868-2"]}}